Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 6;21(11):2065-2080.
doi: 10.7150/ijms.97485. eCollection 2024.

Telomeres and telomerase in Sarcoma disease and therapy

Jin Huang  1   2 , Yan Feng  1   2 , YangJing Shi  3 , Weilin Shao  1   2 , Genshan Li  2 , Gangxian Chen  2 , Ying Li  2 , Zuozhang Yang  2 , Zhihong Yao  1   2
Affiliations
Review

Telomeres and telomerase in Sarcoma disease and therapy

Jin Huang et al. Int J Med Sci. .

Abstract

Sarcoma is a rare tumor derived from the mesenchymal tissue and mainly found in children and adolescents. The outcome for patients with sarcoma is relatively poor compared with that for many other solid malignant tumors. Sarcomas have a highly heterogeneous pathogenesis, histopathology and biological behavior. Dysregulated signaling pathways and various gene mutations are frequently observed in sarcomas. The telomere maintenance mechanism (TMM) has recently been considered as a prognostic factor for patients with sarcomas, and alternative lengthening of telomeres (ALT) positivity has been correlated with poor outcomes in patients with several types of sarcomas. Therefore, telomeres and telomerases may be useful targets for treating sarcomas. This review aims to provide an overview of telomere and telomerase biology in sarcomas.

Keywords: TERT promoter mutation; sarcoma, osteosarcoma; telomerase; telomere shortening; telomeres.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Schematic representation of telomeres, the shelter complex, and telomerase.
See this image and copyright information in PMC

References

    1. Husson O, Drabbe C, Schuster K, van Kampen P, Koops C, Weidema M. et al. Setting the international research agenda for sarcoma together with patients and carers: first results of the Sarcoma Patient EuroNet (SPAEN) priority setting partnership. ESMO Open. 2022;7:100509. - PMC - PubMed
    1. Crompton JG, Ogura K, Bernthal NM, Kawai A, Eilber FC. Local Control of Soft Tissue and Bone Sarcomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2018;36:111–7. - PubMed
    1. Mosku N, Heesen P, Studer G, Bode B, Spataro V, Klass ND, Biopsy Ratio of Suspected to Confirmed Sarcoma Diagnosis. Cancers. 2022. 14. - PMC - PubMed
    1. Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F. et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020;12:e11131. - PMC - PubMed
    1. Li X, Seebacher NA, Hornicek FJ, Xiao T, Duan Z. Application of liquid biopsy in bone and soft tissue sarcomas: Present and future. Cancer letters. 2018;439:66–77. - PubMed